Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	benzodiazepine receptor binding	RIMBP3 RIMBP3C RIMBP3B	4.99e-06	5	160	3	GO:0030156
GeneOntologyMolecularFunction	calcium ion binding	NAALADL1 CDHR2 SYT17 CDHR3 DUOX2 PKD1L2 RYR1 PITPNM1 FAT2 HEG1 CELSR3 RPTN PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	1.11e-04	749	160	17	GO:0005509
GeneOntologyMolecularFunction	modification-dependent protein binding	ING2 DPF2 PHF8 SPIN4 HTATSF1 PLCG2 BAG6 RAD23B	2.62e-04	206	160	8	GO:0140030
GeneOntologyBiologicalProcess	homophilic cell adhesion via plasma membrane adhesion molecules	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	1.36e-05	187	157	9	GO:0007156
GeneOntologyBiologicalProcess	cell-cell adhesion via plasma-membrane adhesion molecules	CDHR2 CDHR3 ITGAL FAT2 TENM4 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	2.89e-05	313	157	11	GO:0098742
GeneOntologyBiologicalProcess	calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules	CDHR3 PCDHGC3 CDH5 PCDH18 CDH16	5.12e-05	53	157	5	GO:0016339
GeneOntologyBiologicalProcess	phospholipase C-inhibiting G protein-coupled receptor signaling pathway	ABL1 PLEK	5.76e-05	2	157	2	GO:0030845
Domain	CADHERIN_1	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	4.98e-07	113	158	9	PS00232
Domain	Cadherin	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	4.98e-07	113	158	9	PF00028
Domain	CADHERIN_2	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	5.37e-07	114	158	9	PS50268
Domain	-	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	5.37e-07	114	158	9	2.60.40.60
Domain	CA	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	5.78e-07	115	158	9	SM00112
Domain	Cadherin-like	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	6.22e-07	116	158	9	IPR015919
Domain	Cadherin	CDHR2 CDHR3 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	7.19e-07	118	158	9	IPR002126
Domain	Cadherin_CS	CDHR2 FAT2 CELSR3 PCDH10 PCDHGC3 CDH5 PCDH18 CDH16	4.05e-06	109	158	8	IPR020894
Domain	CCDC74	CCDC74B CCDC74A	7.11e-05	2	158	2	IPR033226
Domain	CCDC74_C	CCDC74B CCDC74A	7.11e-05	2	158	2	IPR029422
Domain	CCDC74_C	CCDC74B CCDC74A	7.11e-05	2	158	2	PF14917
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	STK36 ABL1 RPS6KA2 SMG5 MED13L ZNF236 STK11IP DENND1A RYR1 ACOX3 RABL6 HIVEP3 PIM3 RADIL HEG1 CELSR3 SBF1 TRAPPC12 PAXIP1 HELZ2 ARC ARRDC2 CABIN1 PC	3.86e-10	1105	162	24	35748872
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	PDS5B NES GALK1 SRSF3 RIOK3 DDX51 PRPF6 MSH3 DPF2 PHF8 RFC2 SUCLG2 ERBIN PDIA3 BUD23 SBF1 GRHPR AKAP10 EIF3B PLCG2 CORO7 BAG6 ZMYM3 SORD	1.98e-08	1353	162	24	29467282
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	PRUNE2 STK36 TBC1D30 ZNF618 ZNF407 VARS2 ARHGEF15 PRX HIVEP3 RADIL FAT2 HELZ2 PCDH18 SLX4	8.99e-08	493	162	14	15368895
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	PRUNE2 KIAA0232 SMG5 MED13L PHF8 ERBIN ARHGEF15 TENM4 HELZ2 DAGLA	1.15e-07	225	162	10	12168954
Pubmed	RIM-BP3 is a manchette-associated protein essential for spermiogenesis.	RIMBP3 RIMBP3C RIMBP3B	3.95e-07	4	162	3	19091768
Pubmed	Structure and evolution of RIM-BP genes: identification of a novel family member.	RIMBP3 RIMBP3C RIMBP3B	9.85e-07	5	162	3	17855024
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	PDS5B GAPVD1 ZEB1 PI4K2A DDX51 NIBAN2 DPF2 PHF8 ERBIN PITPNM1 TRAFD1 HELZ2 EIF3B BAG6 ZMYM3	3.76e-06	774	162	15	15302935
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	VGF NES ZEB1 ZNF618 RPS6KA2 GRM1 ERBIN TXLNA SBF1 CLU PTPRN2 NFATC3 ARC PRKAR2B PPP1R9B CABIN1	1.22e-05	963	162	16	28671696
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	FOXO1 NES GAPVD1 ABL1 KIF26B KIAA0232 RPS6KA2 ERBIN DENND1A RADIL SBF1 NFATC3 PC BECN1 CCDC102A	1.33e-05	861	162	15	36931259
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	PRUNE2 SRSF3 KIAA0232 RPS6KA2 SPTB APP ZNF236 ERBIN DENND1A BRWD3 HIVEP3 PXDN GRK3 PTPRN2 EXOC6B KNDC1 PPP1R9B GPT2 DAGLA MAF	2.16e-05	1489	162	20	28611215
Pubmed	Coordinated roles of SLX4 and MutSβ in DNA repair and the maintenance of genome stability.	MSH3 SLX4	2.16e-05	2	162	2	33596761
Pubmed	Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils.	MMP25 CLU	2.16e-05	2	162	2	12860995
Pubmed	Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity.	APP CLU	2.16e-05	2	162	2	8752142
Pubmed	c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis.	ABL1 APP	2.16e-05	2	162	2	19306298
Pubmed	Clusterin associates specifically with Aβ40 in Alzheimer's disease brain tissue.	APP CLU	2.16e-05	2	162	2	23521156
Pubmed	Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3-9.	SBF1 SUV39H1	2.16e-05	2	162	2	10848615
Pubmed	Synaptic targeting by Alzheimer's-related amyloid beta oligomers.	APP ARC	2.16e-05	2	162	2	15537891
Pubmed	Altered airway and cardiac responses in mice lacking G protein-coupled receptor kinase 3.	GRK2 GRK3	2.16e-05	2	162	2	10198406
Pubmed	Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways.	APP CLU	2.16e-05	2	162	2	28701379
Pubmed	Clusterin contributes to early stage of Alzheimer's disease pathogenesis.	APP CLU	2.16e-05	2	162	2	30295351
Pubmed	G-protein coupled receptor kinase 2 and 3 expression in human detrusor cultured smooth muscle cells.	GRK2 GRK3	2.16e-05	2	162	2	11762794
Pubmed	CCDC74A/B are K-fiber crosslinkers required for chromosomal alignment.	CCDC74B CCDC74A	2.16e-05	2	162	2	31521166
Pubmed	BECN1/Beclin 1 sorts cell-surface APP/amyloid β precursor protein for lysosomal degradation.	APP BECN1	2.16e-05	2	162	2	27715386
Pubmed	Phosphorylation-independent regulation of metabotropic glutamate receptor 1 signaling requires g protein-coupled receptor kinase 2 binding to the second intracellular loop.	GRM1 GRK2	2.16e-05	2	162	2	15870073
Pubmed	Cloning of GRK2 cDNA from S49 murine lymphoma cells.	GRK2 GRK3	2.16e-05	2	162	2	8638670
Pubmed	The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide.	APP CLU	2.16e-05	2	162	2	22179788
Pubmed	The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.	APP CLU	2.16e-05	2	162	2	8328966
Pubmed	Clusterin Binds to Aβ1-42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation.	APP CLU	2.16e-05	2	162	2	26884339
Pubmed	Oncogene SRSF3 suppresses autophagy via inhibiting BECN1 expression.	SRSF3 BECN1	2.16e-05	2	162	2	30654935
Pubmed	Dissecting the roles of GRK2 and GRK3 in μ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells.	GRK2 GRK3	2.16e-05	2	162	2	33060647
Pubmed	G protein--coupled receptor kinases.	GRK2 GRK3	2.16e-05	2	162	2	8035170
Pubmed	Regulation of Abeta pathology by beclin 1: a protective role for autophagy?	APP BECN1	2.16e-05	2	162	2	18497881
Pubmed	Induction of epithelial-mesenchymal transition (EMT) by Beclin 1 knockdown via posttranscriptional upregulation of ZEB1 in thyroid cancer cells.	ZEB1 BECN1	2.16e-05	2	162	2	27683118
Pubmed	PXDN reduces autophagic flux in insulin-resistant cardiomyocytes via modulating FoxO1.	FOXO1 PXDN	2.16e-05	2	162	2	33903591
Pubmed	Correlation between Expression of KLF5 and ZEB1 Transcription Factor Genes in Pancreatic Cancer.	ZEB1 KLF5	2.16e-05	2	162	2	30168064
Pubmed	Integrative characterization of germ cell-specific genes from mouse spermatocyte UniGene library.	RIMBP3 RIMBP3C RIMBP3B	3.48e-05	14	162	3	17662146
Pubmed	Large exons encoding multiple ectodomains are a characteristic feature of protocadherin genes.	FAT2 CELSR3 PCDH10 PCDHGC3 PCDH18	3.74e-05	80	162	5	10716726
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	NES SRSF3 SELENBP1 SPTB GRM1 ERBIN PDIA3 ADD2 PITPNM1 TENM4 GRK2 SBF1 CLU KNDC1 PRKAR2B PPP1R9B CORO7 PC DAGLA	4.11e-05	1431	162	19	37142655
Pubmed	BioID reveals an ATG9A interaction with ATG13-ATG101 in the degradation of p62/SQSTM1-ubiquitin clusters.	PRUNE2 GALK1 TBC1D30 TACC2 MSH3 DENND1A RABL6 TRAPPC12	6.13e-05	285	162	8	34369648
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	PDS5B DCPS PRPF6 DPF2 MED13L RFC2 PDIA3 BUD23 TXLNA KLF5 PAXIP1 ZBTB3 BAG6 ZMYM3 SORD RAD23B	6.20e-05	1103	162	16	34189442
Pubmed	Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309.	GRK2 GRK3	6.45e-05	3	162	2	10754297
Pubmed	The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma.	APP CLU	6.45e-05	3	162	2	7802646
Pubmed	Calcineurin inhibitor protein (CAIN) attenuates Group I metabotropic glutamate receptor endocytosis and signaling.	GRM1 CABIN1	6.45e-05	3	162	2	19717561
Pubmed	The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene.	ABL1 APP	6.45e-05	3	162	2	11279131
Pubmed	PHD finger protein 2 (PHF2) represses ribosomal RNA gene transcription by antagonizing PHF finger protein 8 (PHF8) and recruiting methyltransferase SUV39H1.	PHF8 SUV39H1	6.45e-05	3	162	2	25204660
Pubmed	The identification of human aldo-keto reductase AKR7A2 as a novel cytoglobin-binding partner.	CYGB AKR7A2	6.45e-05	3	162	2	28536627
Pubmed	Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.	ABL1 PHF8	6.45e-05	3	162	2	37469124
Pubmed	Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating Starvation-Induced Autophagy in Cardiac Myocytes.	FOXO1 BECN1	6.45e-05	3	162	2	20947830
Pubmed	Krüppel-like factor 5 accelerates the pathogenesis of Alzheimer's disease via BACE1-mediated APP processing.	APP KLF5	6.45e-05	3	162	2	35883144
Pubmed	Oocyte-specific inactivation of Omcg1 leads to DNA damage and c-Abl/TAp63-dependent oocyte death associated with dramatic remodeling of ovarian somatic cells.	ABL1 ZNF830	6.45e-05	3	162	2	25168238
Pubmed	Regulation of adipocyte differentiation by clusterin-mediated Krüppel-like factor 5 stabilization.	CLU KLF5	6.45e-05	3	162	2	33078455
Pubmed	Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation.	APP ARC	6.45e-05	3	162	2	22036569
Pubmed	Cheliensisin A (Chel A) induces apoptosis in human bladder cancer cells by promoting PHLPP2 protein degradation.	BECN1 PHLPP2	6.45e-05	3	162	2	27556506
Pubmed	Amyloid-β oligomers synaptotoxicity: The emerging role of EphA4/c-Abl signaling in Alzheimer's disease.	ABL1 APP	6.45e-05	3	162	2	29378302
Pubmed	Binding of gelsolin, a secretory protein, to amyloid beta-protein.	APP CLU	6.45e-05	3	162	2	10329371
Pubmed	Direct Interaction of Selenoprotein R with Clusterin and Its Possible Role in Alzheimer's Disease.	APP CLU	6.45e-05	3	162	2	23805218
Pubmed	Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy.	BECN1 PHLPP2	6.45e-05	3	162	2	32116109
Pubmed	SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.	APP SUCLG2	6.45e-05	3	162	2	25027320
Pubmed	BCR-ABL1 alters SDF-1alpha-mediated adhesive responses through the beta2 integrin LFA-1 in leukemia cells.	ABL1 ITGAL	6.45e-05	3	162	2	18339898
Pubmed	Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus.	GRK2 GRK3	6.45e-05	3	162	2	10085131
Pubmed	Amyloid-β oligomers are sequestered by both intracellular and extracellular chaperones.	APP CLU	6.45e-05	3	162	2	23106396
Pubmed	Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor.	GRK2 GRK3	6.45e-05	3	162	2	7761854
Pubmed	The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors.	GRK2 GRK3	6.45e-05	3	162	2	31604529
Pubmed	Identification and characterization of three members of a novel subclass of protocadherins.	PCDH10 PCDH18	6.45e-05	3	162	2	11549318
Pubmed	Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan.	APP CLU	6.45e-05	3	162	2	34298087
Pubmed	Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk.	GRK2 GRK3	6.45e-05	3	162	2	12130708
Pubmed	Cabin1 represses MEF2 transcriptional activity by association with a methyltransferase, SUV39H1.	SUV39H1 CABIN1	6.45e-05	3	162	2	17172641
Pubmed	The cleft palate candidate gene BAG6 supports FoxO1 acetylation to promote FasL-mediated apoptosis during palate fusion.	FOXO1 BAG6	6.45e-05	3	162	2	32991875
Pubmed	In cerebrospinal fluid ER chaperones ERp57 and calreticulin bind beta-amyloid.	APP PDIA3	6.45e-05	3	162	2	15896298
Pubmed	PH domain of G protein-coupled receptor kinase-2 binds to protein kinase C (PKC) and negatively regulates activity of PKC kinase.	GRK2 PLEK	6.45e-05	3	162	2	12456365
Pubmed	Hyperglycemia affects neuronal differentiation and Nestin, FOXO1, and LMO3 mRNA expression of human Wharton's jelly mesenchymal stem cells of children from diabetic mothers.	FOXO1 NES	6.45e-05	3	162	2	36413852
Pubmed	Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non-DRB1 loci.	HLA-DQB1 CYP21A2 VARS2	7.69e-05	18	162	3	19116923
Pubmed	PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.	NIBAN2 APP ERBIN CLU ARC	8.10e-05	94	162	5	32062451
Pubmed	Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.	DENND1A PRX ZFYVE28 HIVEP3 PCDH18	1.14e-04	101	162	5	10997877
Pubmed	Mammalian homolog of Drosophila retinal degeneration B rescues the mutant fly phenotype.	PITPNM1 GRK2	1.29e-04	4	162	2	9221785
Pubmed	Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin.	GRM1 GRK2	1.29e-04	4	162	2	16091361
Pubmed	Krüppel-like factor 5-induced overexpression of long non-coding RNA DANCR promotes the progression of cervical cancer via repressing microRNA-145-3p to target ZEB1.	ZEB1 KLF5	1.29e-04	4	162	2	34233586
Pubmed	ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic Aβ Clearance.	APP BECN1	1.29e-04	4	162	2	27853422
Pubmed	A meta-analysis of genome-wide association studies for serum total IgE in diverse study populations.	HLA-DQB1 SUCLG2	1.29e-04	4	162	2	23146381
Pubmed	Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function.	GRK2 GRK3	1.29e-04	4	162	2	8917529
Pubmed	Neuronal glutathione loss leads to neurodegeneration involving gasdermin activation.	APP GSDMD	1.29e-04	4	162	2	36670138
Pubmed	B cell receptor signaling down-regulates forkhead box transcription factor class O 1 mRNA expression via phosphatidylinositol 3-kinase and Bruton's tyrosine kinase.	FOXO1 PLCG2	1.29e-04	4	162	2	17202334
Pubmed	PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth.	EIF3B PHLPP2	1.29e-04	4	162	2	21986499
Pubmed	p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.	ABL1 RPS6KA2	1.29e-04	4	162	2	21527514
Pubmed	RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1.	ITGAL SUV39H1	1.29e-04	4	162	2	21192791
Pubmed	Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus.	GRK2 GRK3	1.29e-04	4	162	2	23734232
Pubmed	The APP intracellular domain (AICD) potentiates ER stress-induced apoptosis.	APP CLU	1.29e-04	4	162	2	21803450
Pubmed	D-AKAP2, a novel protein kinase A anchoring protein with a putative RGS domain.	PRKAR2B AKAP10	1.29e-04	4	162	2	9326583
Pubmed	Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage.	FOXO1 BECN1	1.29e-04	4	162	2	22622204
Pubmed	Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder.	GRK2 GRK3	1.29e-04	4	162	2	21784156
Pubmed	T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency.	HLA-DQB1 CYP21A2	1.29e-04	4	162	2	19890026
Pubmed	Recent progress in protocadherin research.	CDHR2 PCDH18	1.29e-04	4	162	2	11082270
Pubmed	Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer.	FOXO1 PHLPP2	1.29e-04	4	162	2	25888950
Pubmed	Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C.	GRK2 GRK3	1.29e-04	4	162	2	8662816
Pubmed	Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide.	APP CLU	1.29e-04	4	162	2	9228033
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	PDS5B KIAA0232 MED13L PHF8 ERBIN TENM4 PXDN PCDH10 ZMYM3	1.32e-04	407	162	9	12693553
Pubmed	Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.	SELENBP1 KIAA0232 PI4K2A STK11IP PDIA3 AKR7A2 TBC1D8 TRAFD1 CLU PC PCCB PCDHGC3 BAG6 CDH16 RAD23B	1.41e-04	1061	162	15	33845483
Pubmed	Phosphoproteomic analysis of the developing mouse brain.	PDS5B NES RPS6KA2 ADD2 HTATSF1 ZNF830 EIF3B	1.64e-04	246	162	7	15345747
Pubmed	Developmentally acquired PKA localisation in mouse oocytes and embryos.	PRKAR2B AKAP10	2.14e-04	5	162	2	18367160
Pubmed	APP, APOE, complement receptor 1, clusterin and PICALM and their involvement in the herpes simplex life cycle.	APP CLU	2.14e-04	5	162	2	20674675
Cytoband	15q15.3	DUOX2 ZSCAN29 SORD	9.37e-05	25	162	3	15q15.3
Cytoband	Xp11.23	PAGE4 GAGE2A GAGE2B SUV39H1	3.70e-04	95	162	4	Xp11.23
GeneFamily	Cadherin related	CDHR2 CDHR3 FAT2	1.09e-04	17	101	3	24
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	SPTB GRK2 GRK3 SBF1 PLEK PHLPP2	1.05e-03	206	101	6	682
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Alv_Cap\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	NES CCDC74B ZEB1 RPS6KA2 APP ARHGEF15 PRX HEG1 PINX1 ARRDC2 CDH5	1.65e-10	200	159	11	b7533c571eeea0cb3678e1a57d3dc036fa8d0f49
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ZEB1 APP ARHGEF15 PRX TBC1D8 HIVEP3 CSRNP1 HEG1 ARRDC2 CDH5	2.62e-09	198	159	10	92416e65a0dc1a4bf931833407620ea05d362f56
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ZEB1 APP ARHGEF15 PRX HEG1 CLU GSDMD HELZ2 PINX1 CDH5	2.89e-09	200	159	10	89821a264e872ed53e08e9d3609d5cc5c314503e
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_aerocyte_capillary-EC_aerocyte_capillary_L.2.0.1.2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NES ZEB1 APP ARHGEF15 PRX PXDN ARC PCDH10 CDH5	3.81e-08	196	159	9	a53caedd0103bd162b3aee8ab87b4442a5e0338f
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	NES ZEB1 APP ARHGEF15 PRX HEG1 HELZ2 PINX1 CDH5	4.53e-08	200	159	9	bcd1cc96197929d6011903803b6f4ccdcf52b4ce
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Alv_Cap\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	NES ZEB1 RPS6KA2 ARHGEF15 PRX PINX1 PPP1R9B ARRDC2 CDH5	4.53e-08	200	159	9	66f7e8ee63c828f17468e79a4b816346b33e8980
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Alv_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	NES ZEB1 APP ARHGEF15 PRX PINX1 PPP1R9B ARRDC2 CDH5	4.53e-08	200	159	9	7034f57e282982c19c13ee8ab78eabaffa069e30
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX HEG1 PINX1 PPP1R9B CDH5	4.53e-08	200	159	9	a1fa6bae5a688faf488d6925cd3fad725dfa916b
ToppCell	LPS_IL1RA_TNF-Endothelial\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX HEG1 PINX1 PPP1R9B CDH5	4.53e-08	200	159	9	d01cec331be3b03cef80e9536fc531285bcf00f6
ToppCell	LPS_only-Endothelial-Endothelial-Alv_Cap\|LPS_only / Treatment groups by lineage, cell group, cell type	NES ZEB1 APP ARHGEF15 PRX HEG1 PINX1 PPP1R9B CDH5	4.53e-08	200	159	9	432384faeade8e609154fab3d96c955a8ec868dd
ToppCell	Bronchial-10x5prime-Endothelial-Endothelia_vascular-VE_alveolar_capillary_Car4_aerocyte\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NES ZEB1 RPS6KA2 ARHGEF15 PRX PXDN ARC CDH5	6.09e-07	199	159	8	7ed541309808f15d65a9c4b26be2050e077539e6
ToppCell	distal-Endothelial-Capillary_Intermediate_2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NES ZEB1 RPS6KA2 APP PRX PTPRN2 ARRDC2 CDH5	6.09e-07	199	159	8	b44712baede833ddbac3699162b7eeb6ede2af27
ToppCell	distal-Endothelial-Capillary_Intermediate_2-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NES ZEB1 RPS6KA2 APP PRX PTPRN2 ARRDC2 CDH5	6.09e-07	199	159	8	a5c2c676fc0dd4f0422fbcae34ad6d734edd5349
ToppCell	LPS_IL1RA-Endothelial-Endothelial\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX HEG1 PINX1 CDH5	6.33e-07	200	159	8	72ea9882a8ed26fa1534aeb6ba0d1897dccc20c5
ToppCell	Parenchyma_COVID-19-Endothelial-TX-Capillary\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	NES ZEB1 ARHGEF15 PRX HEG1 PXDN ARC CDH5	6.33e-07	200	159	8	6c0498a5868891e8e22c03469d00669b20249b1a
ToppCell	LPS_IL1RA-Endothelial\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX HEG1 PINX1 CDH5	6.33e-07	200	159	8	5c092b2ecc081b5d04476c56333c338cd89ab984
ToppCell	LPS_only-Endothelial\|LPS_only / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX HEG1 PINX1 CDH5	6.33e-07	200	159	8	81e76508c9050d533853d5fd2f3097b27613d836
ToppCell	Lung_Parenchyma-Severe-Endothelial-Endothelial-Capillary-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NES ZEB1 ARHGEF15 PRX HEG1 PXDN ARC CDH5	6.33e-07	200	159	8	7020045b933cb104fb99b79524cb0d4734b8636d
ToppCell	Control_saline-Endothelial-Endothelial-Alv_Gen_Intermediate\|Control_saline / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX PINX1 PPP1R9B CDH5	6.33e-07	200	159	8	041a34080120c9f613373c20dcc366292f558040
ToppCell	Control_saline-Endothelial-Endothelial\|Control_saline / Treatment groups by lineage, cell group, cell type	ZEB1 APP ARHGEF15 PRX HEG1 PINX1 PPP1R9B CDH5	6.33e-07	200	159	8	e77eba6172cabf85b8028638ed35299f2f079cd8
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Activated_Alv_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	NES ZEB1 APP ARHGEF15 PRX HEG1 PINX1 CDH5	6.33e-07	200	159	8	79e51afb57ca38aacebd0298e5e727b55c0cfff9
ToppCell	Biopsy_Other_PF-Endothelial-Endothelial_cells\|Biopsy_Other_PF / Sample group, Lineage and Cell type	NES ZEB1 APP ARHGEF15 PRX HEG1 CLU CDH5	6.33e-07	200	159	8	40d57a383c79d3365e033d08efd9371f0bc5bf55
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Alv_Gen_Intermediate\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX PINX1 PPP1R9B CDH5	6.33e-07	200	159	8	89a6da2bdedc6b1ad0675c8753bf2b763a99af6a
ToppCell	Lung_Parenchyma-Severe-Endothelial-Endothelial-Capillary\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	NES ZEB1 ARHGEF15 PRX HEG1 PXDN ARC CDH5	6.33e-07	200	159	8	e9913511a129bb3cee85e7ebf565b951dab91542
ToppCell	LPS_anti-TNF-Endothelial\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ZEB1 APP ARHGEF15 PRX HEG1 PINX1 PPP1R9B CDH5	6.33e-07	200	159	8	1d105eeda5a2c51f9a4654ffc79b7e2348ad593b
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Alv_Gen_Intermediate\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX PINX1 PPP1R9B CDH5	6.33e-07	200	159	8	58a7ece7dfdf6c46f2a50cbcb580574dec14c748
ToppCell	LPS_anti-TNF-Endothelial-Endothelial\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ZEB1 APP ARHGEF15 PRX HEG1 PINX1 PPP1R9B CDH5	6.33e-07	200	159	8	60d2cbf41f37f1b11eddb4c9d9246c9c1fc5a5af
ToppCell	Control_saline-Endothelial\|Control_saline / Treatment groups by lineage, cell group, cell type	ZEB1 APP ARHGEF15 PRX HEG1 PINX1 PPP1R9B CDH5	6.33e-07	200	159	8	3372c488a39fe812fa94e4f0564594186fea3db5
ToppCell	LPS_only-Endothelial-Endothelial-Artery\|LPS_only / Treatment groups by lineage, cell group, cell type	RPS6KA2 ARHGEF15 HEG1 CLU ARC PINX1 PCDH10 CDH5	6.33e-07	200	159	8	b17eb1587ca86c3d40515128a00a8d8fd787fccf
ToppCell	LPS_only-Endothelial-Endothelial\|LPS_only / Treatment groups by lineage, cell group, cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX HEG1 PINX1 CDH5	6.33e-07	200	159	8	4bb609a284d4e6066f17470a1736076aa4a1f84c
ToppCell	droplet-Lung-21m-Hematologic-lymphocytic-mature_NK_T_cell-mature_NK_T_cell_l44\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CDHR3 MSH3 STK11IP RYR1 FANCF BECN1 RAD23B	3.00e-06	173	159	7	b6bb2a136a40f0946bbcde8d5972d3f059d080c7
ToppCell	droplet-Lung-21m-Epithelial-airway_epithelial-lung_ciliated_cell\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STK36 CDHR3 RASSF10 TNN TTC29 CCDC74A KNDC1	3.49e-06	177	159	7	d947ba38db1772fc5fdcdc211f7511c4aa699dee
ToppCell	droplet-Lung-21m-Epithelial-airway_epithelial-lung_ciliated_cell-ciliated_cell\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	STK36 CDHR3 RASSF10 TNN TTC29 CCDC74A KNDC1	3.49e-06	177	159	7	d5640f0097878f0dac671e51dc51310278bb2682
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PRUNE2 SPTB CYGB GRM1 ITGAL RYR1 FAT2	3.90e-06	180	159	7	6ac62bf1251978c8c12e715f7b73144fca619794
ToppCell	Fetal_29-31_weeks-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ZEB1 KIF26B APP PRX PXDN HELZ2 CDH5	3.90e-06	180	159	7	d8ef44710a77ad0fc03243428e5e1dc4d41200cb
ToppCell	COVID-19-Endothelial_cells-Capillary_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	4.05e-06	181	159	7	c5f9c92af1384d9089c65afdf41c6feb8345a3ae
ToppCell	Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D175\|Adult / Lineage, Cell type, age group and donor	NES ZEB1 ARHGEF15 PRX PXDN ARC CDH5	4.20e-06	182	159	7	8b4a07ebd7a133a33ef333cfa29d12c4f3d4d9ac
ToppCell	droplet-Kidney-nan-18m\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APP SUCLG2 ERBIN PIM3 CDH16 SORD MAF	4.51e-06	184	159	7	e02859bbac36dbbd55d7ae8cb5e46b764d7c6381
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-5_PVALB_TRIM67\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIF26B RPS6KA2 PKD1L2 GRM1 KLF5 TTC29 MAF	4.51e-06	184	159	7	7f6c8912677764d438ab0555faca344d74c2f483
ToppCell	356C-Endothelial_cells-Endothelial-C_(Capillary_Aerocyte_)-\|356C / Donor, Lineage, Cell class and subclass (all cells)	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	4.84e-06	186	159	7	f0b78c7ee20279970ea8961bf59acb5262f2dce5
ToppCell	356C-Endothelial_cells-Endothelial-C_(Capillary_Aerocyte_)\|356C / Donor, Lineage, Cell class and subclass (all cells)	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	4.84e-06	186	159	7	2b3c814a7dee8286ea113c63dc3de5daf0257d37
ToppCell	3'-Adult-LargeIntestine-Hematopoietic-Myeloid-Lymphoid_DC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IL10RA KIF26B HLA-DQB1 TBC1D8 FAT2 GRK3 PLEK	5.01e-06	187	159	7	d69f4eee0304a7db226275ab77fc9d5d2b6f3a07
ToppCell	Fetal_29-31_weeks-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NES ZEB1 RPS6KA2 APP ARHGEF15 PRX CDH5	5.01e-06	187	159	7	97b2463fb37e7196dd2f92553acf8e7bc3ec40dd
ToppCell	Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)\|Adult / Lineage, Cell type, age group and donor	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	5.19e-06	188	159	7	e5cad03f4a64147fe8174e7f614cf45233ffb9b7
ToppCell	LAM-Endothelial-VasEndo-1\|LAM / Condition, Lineage and Cell class	NES APP ARHGEF15 PRX PXDN ARC CDH5	5.38e-06	189	159	7	454e64b1ee93edebbc1576fbf7c3a6db332fa927
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NES ZEB1 RPS6KA2 GASK1B ARHGEF15 HEG1 CDH5	5.57e-06	190	159	7	bf9bc57a605c7e3979bc4f7260e6fb92c3eb8690
ToppCell	facs-Heart-LA-24m-Endothelial\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NES KRT32 RPS6KA2 ARHGEF15 CLU ARC CDH5	5.57e-06	190	159	7	911b93c4c828ef2d867b91a5eced2dc12a1baf27
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	5.57e-06	190	159	7	0e9847d7f49b2236b8a191e1a7df37556351ba9e
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	5.57e-06	190	159	7	0a351609a72fd638c84b2435782e312ee6a33aac
ToppCell	Endothelial-A-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	NES ZEB1 ARHGEF15 HEG1 PXDN CLU CDH5	5.76e-06	191	159	7	f702dfe88a9b04091dae87df61b2b4f43525f86a
ToppCell	BAL-Control-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CCDC74B SELENBP1 CDHR3 TACC2 CLU TTC29 CCDC74A	5.76e-06	191	159	7	9f19098f260d5542aa8ba7eb6f91b44d0db6e0a4
ToppCell	BAL-Control-Epithelial-Epithelial-Ciliated-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC74B SELENBP1 CDHR3 TACC2 CLU TTC29 CCDC74A	5.76e-06	191	159	7	fa9f8b50bfc7911c858bc2f9dcd204873d97ac61
ToppCell	Fetal_29-31_weeks-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NES ZEB1 RPS6KA2 APP ARHGEF15 PRX CDH5	5.76e-06	191	159	7	1de0bdfd13bd930691564c2673f2e66393bc0255
ToppCell	BAL-Control-Epithelial-Epithelial-Ciliated\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCDC74B SELENBP1 CDHR3 TACC2 CLU TTC29 CCDC74A	5.76e-06	191	159	7	c4b223b33c020a064f576711a3d700eb60a2d737
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	5.76e-06	191	159	7	f229abf69a1217194f74b0502486907e07dba989
ToppCell	BAL-Control-Epithelial-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CCDC74B SELENBP1 CDHR3 TACC2 CLU TTC29 CCDC74A	5.76e-06	191	159	7	df8a1a6e78aa0cb941b94cb676bd6891d79f3687
ToppCell	Control-Epithelial\|Control / Disease group,lineage and cell class （2021.01.30）	CCDC74B SELENBP1 CDHR3 TACC2 CLU TTC29 CCDC74A	5.76e-06	191	159	7	b78547dae8328244a47c83346447bdd787efbcae
ToppCell	facs-Thymus-Epithelium-24m-Endothelial\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NES APP GASK1B ARHGEF15 PXDN CLU CDH5	5.96e-06	192	159	7	39afea574725ce0c67afdd79facdb34f819a828d
ToppCell	facs-Thymus-Epithelium-24m-Endothelial-endothelial_cell\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NES APP GASK1B ARHGEF15 PXDN CLU CDH5	5.96e-06	192	159	7	597db951b1fbc37db22134c3d27d3ec4ceaa85f7
ToppCell	Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)\|World / Lineage, Cell type, age group and donor	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	5.96e-06	192	159	7	1e156bab5ecf64627890d2de9b27603d9a01f28d
ToppCell	facs-Thymus-Epithelium-24m-Endothelial-endothelial_cell\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NES APP GASK1B ARHGEF15 PXDN CLU CDH5	5.96e-06	192	159	7	bc275a9eccb1c7a46fd58b15ca5acdd9f7495842
ToppCell	Fetal_29-31_weeks-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NES ZEB1 RPS6KA2 APP ARHGEF15 PRX CDH5	5.96e-06	192	159	7	7197e401e563441ab94815f7619e032ebef9e586
ToppCell	human_hepatoblastoma-Endothelial_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	RPS6KA2 APP ARHGEF15 ZFYVE28 HIVEP3 PXDN CDH5	5.96e-06	192	159	7	e09f609fed033a25baacaf4a07bbbae1076da366
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Cbln4\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ZNF618 RASSF10 GRM1 KLF5 PCDH18 MAF	6.15e-06	126	159	6	94bd9cfe982b41a3114885173eab55feb0fbbbae
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Calb2_Necab1\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SPTB RASSF10 GRM1 KLF5 PCDH18 MAF	6.15e-06	126	159	6	a4fc7ac4931d2fc8aa8196a62d809b698937aa9c
ToppCell	tumor_Lung-Endothelial_cells-Stalk-like_ECs\|tumor_Lung / Location, Cell class and cell subclass	APP ARHGEF15 HEG1 CLU ARC PCDH10 CDH5	6.17e-06	193	159	7	21fec35587ffb5c0157e54a821ce3ffd3e24e536
ToppCell	3'-Broncho-tracheal-Endothelial-Blood_vessel_EC\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NES ZEB1 GASK1B ARHGEF15 HEG1 CLU CDH5	6.38e-06	194	159	7	3446bbe12767fc2006c5d6a39758f31d8f899409
ToppCell	IPF-Endothelial-VE_Capillary_B\|IPF / Disease state, Lineage and Cell class	NES ZEB1 ARHGEF15 PRX HEG1 PXDN CDH5	6.38e-06	194	159	7	169a304d5c13f08c39fad4116f093bc4a0765e9d
ToppCell	COVID-19-kidney-Glomerular_EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ZEB1 APP ARHGEF15 TBC1D8 PLCG2 CDH5 MAF	6.38e-06	194	159	7	660535b492445063d965095a50e1e299ce04c50a
ToppCell	wk_20-22-Endothelial-Blood_vessel_endothelial-Aerocyte\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	NES ZEB1 APP ARHGEF15 PRX ARC CDH5	6.38e-06	194	159	7	54b7126b83f7482227aeaea065f504b65fa34bfe
ToppCell	3'-Broncho-tracheal-Endothelial\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NES ZEB1 GASK1B ARHGEF15 HEG1 CLU CDH5	6.38e-06	194	159	7	8b6d13cfd04f7ff0847ad7cfbbca4e66e07b8344
ToppCell	LAM-Endothelial\|LAM / Condition, Lineage and Cell class	NES ZEB1 APP ARHGEF15 PRX HEG1 CDH5	6.38e-06	194	159	7	1241e3e75414b619abc9431627619f5c194ec930
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ZEB1 ARHGEF15 PRX TBC1D8 HIVEP3 HEG1 CDH5	6.60e-06	195	159	7	23ced69fd904f1d4114b1a7f99f4b5f65ea8824b
ToppCell	343B-Endothelial_cells-Endothelial-D\|343B / Donor, Lineage, Cell class and subclass (all cells)	NES ZEB1 APP SPIN4 HEG1 CLU CDH5	6.82e-06	196	159	7	99953fe0a40e242f6945150345fc0a08ed95f8f9
ToppCell	E16.5-Epithelial-Epithelial_Alveolar\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RASSF10 APP CLU KLF5 BEND7 MAPK13 CDH16	6.82e-06	196	159	7	1756254a61ea92601ed5e223ef4471f010c12216
ToppCell	Adult-Immune-monocyte\|Adult / Lineage, Cell type, age group and donor	IL10RA ITGAL DENND1A TBC1D8 GRK2 GRK3 PLEK	6.82e-06	196	159	7	3ef193c5180de3137daf886492e74fc574bc9767
ToppCell	COVID-19-lung-Capillary_Aerocytes\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ZEB1 RPS6KA2 APP ARHGEF15 PRX PXDN CDH5	6.82e-06	196	159	7	49cc0a2b9739abad61dff7292ea0b14d28ff35c4
ToppCell	343B-Endothelial_cells-Endothelial-D-\|343B / Donor, Lineage, Cell class and subclass (all cells)	NES ZEB1 APP SPIN4 HEG1 CLU CDH5	6.82e-06	196	159	7	5edffdc4c1ff35d9ee0e5c1bed0dc0c90b76ea00
ToppCell	E16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-Sox9_Epi\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RASSF10 APP CLU KLF5 BEND7 MAPK13 CDH16	6.82e-06	196	159	7	b236be2fc0144c77a8840081bbb6ac6913e996f8
ToppCell	mild_COVID-19_(asymptomatic)\|World / disease group, cell group and cell class (v2)	RIOK3 MED13L ERBIN HIVEP3 GRK3 PLCG2 PLEK	6.82e-06	196	159	7	8cb3dcb3e5732f4bb060c87ca339b8997a1a8cd4
ToppCell	E16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RASSF10 APP CLU KLF5 BEND7 MAPK13 CDH16	6.82e-06	196	159	7	caa3c9555e1c656e88246ed31388a818f77610a1
ToppCell	3'-Broncho-tracheal-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic-EC_venous_systemic_L.2.2.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NES ZEB1 GASK1B ARHGEF15 HEG1 PXDN CDH5	7.05e-06	197	159	7	78bc83cd5546c7dd128e6791acda97f55089bc1c
ToppCell	3'-Parenchyma_lung-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_aerocyte_capillary-EC_aerocyte_capillary_L.2.0.1.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NES APP PRX CSRNP1 ARC ARRDC2 CDH5	7.05e-06	197	159	7	86591849476b3925857a82b6913f65e74df200c1
ToppCell	(4)_Blood_vessel\|World / Oesophagus cell shreds on cell class (v1) and cell subclass (v1)	ZEB1 CYGB GASK1B ARHGEF15 HEG1 CLU CDH5	7.05e-06	197	159	7	1b82979a41ef46c814c82527a585900586d71260
ToppCell	5'-Adult-Appendix-Endothelial-blood_vessel_EC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NES RPS6KA2 GASK1B ARHGEF15 HEG1 CLU CDH5	7.05e-06	197	159	7	e8e879b7634a29569061d3515d180784094a31e7
ToppCell	3'-Parenchyma_lung-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_general_capillary-EC_general_capillary_L.2.0.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NES ZEB1 APP ARHGEF15 HEG1 PXDN CDH5	7.05e-06	197	159	7	15d1e0dffee8f5ba8cee37adfbfa0551a0cd5e15
ToppCell	5'-Adult-Appendix-Endothelial-lymphatic_endothelial-LEC1_(ACKR4+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ZNF407 GASK1B PIM3 PXDN DNAJB5 CDH5 BAG6	7.05e-06	197	159	7	789c97ca9d1e28df3353140046047f11fbccc1d0
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ZEB1 APP ARHGEF15 PRX HIVEP3 HEG1 CDH5	7.29e-06	198	159	7	1378c6d4ceb84b42fdd6556be3296df7a8059e6e
ToppCell	343B-Endothelial_cells\|343B / Donor, Lineage, Cell class and subclass (all cells)	NES ZEB1 APP ARHGEF15 PRX HEG1 CDH5	7.29e-06	198	159	7	fab32347580c7a81ef1fe4fe7b325d9105a947d9
ToppCell	COVID-19_Mild\|World / Disease condition and Cell class	IL10RA MED13L ITGAL PIM3 GRK2 PLCG2 PLEK	7.29e-06	198	159	7	61ceb2245b6cb58e308b999a61d218c89dbc615e
ToppCell	NS-critical-LOC-Epithelial-Secretory_LYPD2\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	SELENBP1 DUOX2 TACC2 CLU KLF5 PRKAR2B SORD	7.29e-06	198	159	7	4a481e1edb80b950c823ed926842cd5132cfb27f
ToppCell	kidney_cells-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ZEB1 APP ARHGEF15 PRX HEG1 ARRDC2 CDH5	7.53e-06	199	159	7	5d976d57872a8a25a11fe8cd53b01aa21a1a519a
ToppCell	Parenchymal-NucSeq-Endothelial-Endothelia_vascular-VE_alveolar_capillary_Car4_aerocyte\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NES ZEB1 APP ARHGEF15 PRX PXDN CDH5	7.53e-06	199	159	7	dc88ce36cc066eb6c28cfd5b9b60fe07f8cc7b53
ToppCell	cellseq-Endothelial-Endothelial_Vascular\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NES ZEB1 APP PRX CSRNP1 HEG1 CDH5	7.53e-06	199	159	7	307d29816a224193aa3d8c4540e128b2ad2e90b9
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Vein\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	FOXO1 APP HEG1 CLU PINX1 PCDH10 CDH5	7.53e-06	199	159	7	cfb624c7728046fc7f3ef071f57e4d7b013f3fef
ToppCell	Parenchymal-10x5prime-Endothelial-Endothelia_vascular-VE_alveolar_capillary_Car4_aerocyte\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NES ZEB1 APP PRX PXDN ARC CDH5	7.53e-06	199	159	7	14a7c4cf4bb3d43fd32ec9cc74f6625b225ffaa1
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_general_capillary-EC_general_capillary_L.2.0.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NES APP ARHGEF15 PRX CSRNP1 ARRDC2 CDH5	7.78e-06	200	159	7	ec9a18576a3d08ddfceb70d114c4ab861fbb0d08
ToppCell	Bronchial-10x5prime-Endothelial-Endothelia_vascular-VE_capillary\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NES ARHGEF15 PRX HEG1 PXDN ARC CDH5	7.78e-06	200	159	7	5ab588808c1fc384019413401ab4bf9bc06bf529
ToppCell	Biopsy_Other_PF-Endothelial\|Biopsy_Other_PF / Sample group, Lineage and Cell type	NES ZEB1 APP ARHGEF15 HEG1 CLU CDH5	7.78e-06	200	159	7	f9916134486fb1dac55f5e7e8deb35e7a3b85770
ToppCell	Parenchymal-10x5prime-Endothelial-Endothelia_vascular\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NES APP ARHGEF15 PRX HEG1 PXDN CDH5	7.78e-06	200	159	7	2989325b0e78ab42f362cfb59e34a4fce7f8e869
Drug	Austricine [10180-88-8]; Down 200; 14.2uM; PC3; HT_HG-U133A	RALGDS GALK1 PI4K2A SMG5 TSC22D2 GRM1 HEG1 SLC9A3 GRK2 PTPRN2 DNAJB5 MPPE1	1.52e-08	200	157	12	4213_DN
Drug	BiM4	RPS6KA2 APP GRM1 SUCLG2 PIM3 GRK2 GRK3 CELSR3 PRKAR2B PLCG2 PLEK MAPK13 CDH5	8.85e-08	283	157	13	CID000002399
Drug	(-)-Cinchonidine [485-71-2]; Up 200; 13.6uM; HL60; HG-U133A	CDHR2 KRT32 SPTB SMG5 ZNF236 ACOX3 PXDN TNN AKAP10 MPPE1	1.28e-06	199	157	10	1780_UP
Drug	NSC618487	VGF STK36 ABL1 RPS6KA2 CYP21A2 CYGB DUOX2 APP GRM1 ITGAL GRK2 GRK3 CLU PAXIP1 PRKAR2B PLCG2 PLEK MAPK13 CABIN1 DAGLA	6.92e-06	933	157	20	CID000005279
Drug	yohimbine; Up 200; 22.9uM; MCF7; HT_HG-U133A_EA	PDS5B GALK1 APP ACOX3 RABL6 CELSR3 ZBTB3 PC MPPE1	8.40e-06	194	157	9	1119_UP
Drug	Fenspiride hydrochloride [5053-08-7]; Down 200; 13.4uM; PC3; HT_HG-U133A	PDS5B RPS6KA2 ZNF236 FANCF TXLNA SBF1 HTATSF1 MPPE1 RAD23B	8.40e-06	194	157	9	2106_DN
Drug	alpha-estradiol; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA	PDS5B GALK1 PRPF6 APP ACOX3 TRAFD1 CELSR3 AKAP10 MPPE1	8.40e-06	194	157	9	990_DN
Drug	Chelidonine monohydrate (+) [476-32-4]; Up 200; 10.8uM; PC3; HT_HG-U133A	CDHR2 SYT17 APP ADD2 HEG1 CLU PTPRN2 KLF5 ARC	8.76e-06	195	157	9	5760_UP
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; PC3; HT_HG-U133A	TBC1D30 RPS6KA2 ACOX3 ADD2 HIVEP3 GRK3 GSDMD ARC PLCG2	9.13e-06	196	157	9	3762_DN
Drug	Alfadolone acetate [23930-37-2]; Up 200; 10.2uM; PC3; HT_HG-U133A	ZEB1 RPS6KA2 PI4K2A DUOX2 ZNF407 GRM1 DNAJB5 CABIN1 RAD23B	9.51e-06	197	157	9	7262_UP
Drug	Fenbufen [36330-85-5]; Up 200; 15.8uM; MCF7; HT_HG-U133A	RPS6KA2 PI4K2A PHF8 ARHGEF15 HIVEP3 TENM4 CLU NFATC3 PLEK	9.51e-06	197	157	9	2308_UP
Drug	Bromopride [4093-35-0]; Up 200; 11.6uM; MCF7; HT_HG-U133A	PRUNE2 ZEB1 SPTB DDX51 TSC22D2 PITPNM1 MMP25 PLEK DNAJB5	9.90e-06	198	157	9	6037_UP
Drug	Evoxine [522-11-2]; Down 200; 11.6uM; PC3; HT_HG-U133A	GALK1 KIAA0232 SPTB SMG5 ZNF236 HIVEP3 SBF1 EXOC6B ARC	9.90e-06	198	157	9	3681_DN
Drug	Hydroquinine hydrobromide hydrate [304695-81-6]; Down 200; 9.4uM; MCF7; HT_HG-U133A	VGF PI4K2A TXLNA CELSR3 SBF1 PLCG2 DNAJB5 CABIN1 PC	9.90e-06	198	157	9	2767_DN
Drug	Pyrimethamine [58-14-0]; Down 200; 16uM; PC3; HT_HG-U133A	ZEB1 PI4K2A TSC22D2 APP GRM1 PITPNM1 HIVEP3 HEG1 MAF	9.90e-06	198	157	9	4194_DN
Drug	Methamphetamine	VGF PRUNE2 GALK1 ABL1 CDHR2 SYT17 TACC2 GRM1 STK11IP PDIA3 ARHGEF15 ACOX3 ADD2 AKR7A2 SBF1 NFATC3 TRAPPC12 KLF5 KNDC1 ARC DNAJB5 ARRDC2 CABIN1 BECN1 MPPE1	1.12e-05	1401	157	25	ctd:D008694
Drug	Cocaine	FOXO1 GALK1 ABL1 SRSF3 CYGB DPF2 APP GRM1 ERBIN PDIA3 PIM3 TENM4 GRK2 CLU KLF5 SUV39H1 ARC PINX1 EIF3B CORO7 TXN2 PCDHGC3 CDH16 PHLPP2	1.17e-05	1314	157	24	ctd:D003042
Drug	AC1Q6RZ4	GALK1 RYR1 GRK2 GRK3 PRKAR2B PC BAG6	2.36e-05	123	157	7	CID000000719
Drug	phorbol acetate myristate	VGF KRT32 RPS6KA2 ETV4 APP GRM1 ITGAL PDIA3 PRX RYR1 AKR7A2 SLC9A3 GRK2 GRK3 PTPRN2 NFATC3 KLF5 PRKAR2B PLCG2 PLEK MAPK13 CABIN1 DAGLA MAF	3.26e-05	1399	157	24	CID000004792
Drug	2,3,6,2',3',6'-hexachlorobiphenyl	RYR1 ARC PPP1R9B	5.10e-05	11	157	3	ctd:C010498
Drug	2,4,5,2',5'-pentachlorobiphenyl	PRUNE2 ZEB1 DCPS TROAP KIF26B CYP21A2 ZNF397 APP BRWD3 ARHGEF15 PRX RYR1 ACOX3 PITPNM1 FAT2 GRK3 CELSR3 PTPRN2 BEND7 CCDC74A HELZ2 KNDC1 AKAP10 CDH5	5.21e-05	1441	157	24	ctd:C009828
Drug	Harmol hydrochloride monohydrate [40580-83-4]; Up 200; 15.8uM; MCF7; HT_HG-U133A	VGF CDHR2 KIAA0232 MMP25 HEG1 TRAFD1 MAPK13 DAGLA	6.00e-05	193	157	8	6022_UP
Drug	Isoxsuprine hydrochloride [579-56-6]; Down 200; 11.8uM; HL60; HG-U133A	DCPS MED13L RFC2 APP GRK2 SBF1 EIF3B RAD23B	6.45e-05	195	157	8	1985_DN
Drug	Metyrapone [54-36-4]; Down 200; 17.6uM; MCF7; HT_HG-U133A	FOXO1 NES CDHR2 TRAFD1 GRK2 NFATC3 KLF5 MAPK13	6.45e-05	195	157	8	5667_DN
Drug	Ursolic acid [77-52-1]; Down 200; 8.8uM; PC3; HT_HG-U133A	KIAA0232 RPS6KA2 PRPF6 SMG5 ADD2 RABL6 CLU CABIN1	6.45e-05	195	157	8	5825_DN
Drug	Benperidol [2062-84-2]; Down 200; 10.4uM; PC3; HT_HG-U133A	GRM1 HEG1 GRK3 SBF1 PLCG2 DNAJB5 MPPE1 MAF	6.69e-05	196	157	8	4196_DN
Drug	BAS 012416453; Up 200; 38uM; MCF7; HT_HG-U133A	DDX51 APP ACOX3 MMP25 HEG1 GRK2 SBF1 MPPE1	6.69e-05	196	157	8	6880_UP
Drug	Cefamandole sodium salt [30034-03-8]; Up 200; 8.2uM; PC3; HT_HG-U133A	ZEB1 TBC1D30 GRM1 ACOX3 ADD2 TRAFD1 GRK3 PTPRN2	6.69e-05	196	157	8	3696_UP
Drug	Napelline [5008-52-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A	SPTB DDX51 GRM1 RYR1 PITPNM1 GRK2 NFATC3 PHLPP2	6.69e-05	196	157	8	6824_UP
Drug	Ampyrone [83-07-8]; Up 200; 19.6uM; MCF7; HT_HG-U133A	DDX51 TSC22D2 GRM1 ZNF236 RYR1 MMP25 SBF1 DNAJB5	6.69e-05	196	157	8	6845_UP
Drug	AC1MRDQ4	ACOX3 AKR7A2 PCCB	6.76e-05	12	157	3	CID003491289
Drug	Benzylpenicillin sodium [69-57-8]; Up 200; 11.2uM; MCF7; HT_HG-U133A	CDHR2 RPS6KA2 PI4K2A GRM1 RYR1 MMP25 PLEK MAF	6.93e-05	197	157	8	3577_UP
Drug	Ticarcillin sodium [4697-14-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A	VGF FOXO1 PDS5B TROAP SBF1 NFATC3 CABIN1 PC	6.93e-05	197	157	8	7185_DN
Drug	Urapidil hydrochloride [64887-14-5]; Down 200; 9.4uM; MCF7; HT_HG-U133A	VGF NES GALK1 SMG5 MSH3 HIVEP3 ARC MPPE1	6.93e-05	197	157	8	6455_DN
Drug	Cephapirin sodium salt [24356-60-3]; Up 200; 9uM; PC3; HT_HG-U133A	CDHR2 APP PTPRN2 NFATC3 GSDMD AKAP10 DNAJB5 MPPE1	6.93e-05	197	157	8	7142_UP
Drug	Suprofen [40828-46-4]; Down 200; 15.4uM; PC3; HT_HG-U133A	RALGDS APP GRM1 ITGAL HIVEP3 GRK3 EXOC6B CABIN1	7.18e-05	198	157	8	4005_DN
Drug	Triamterene [396-01-0]; Up 200; 15.8uM; PC3; HT_HG-U133A	RALGDS SYT17 APP HEG1 GRK2 PTPRN2 DNAJB5 RAD23B	7.18e-05	198	157	8	7307_UP
Drug	11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A	SYT17 PI4K2A TSC22D2 RABL6 HIVEP3 CLU HTATSF1 DNAJB5	7.18e-05	198	157	8	7519_DN
Drug	Gentamicine sulfate [1405-41-0]; Down 200; 2.6uM; MCF7; HT_HG-U133A	VGF RPS6KA2 SMG5 APP ACOX3 TRAFD1 GRK2 NFATC3	7.44e-05	199	157	8	7237_DN
Drug	Foliosidine [2520-38-9]; Up 200; 13uM; PC3; HT_HG-U133A	ZNF407 DDX51 TSC22D2 PTPRN2 EXOC6B ARC PLEK DAGLA	7.44e-05	199	157	8	4295_UP
Drug	C070379	GRM1 RYR1 SLC9A3 GRK2 GRK3 PRKAR2B PLEK MAPK13	7.44e-05	199	157	8	CID003034747
Drug	Acetopromazine maleate salt [3598-37-6]; Down 200; 9uM; MCF7; HT_HG-U133A	TBC1D30 PI4K2A APP GRK2 CELSR3 AKAP10 CABIN1 MPPE1	7.44e-05	199	157	8	2769_DN
Drug	Amiprilose hydrochloride [60414-06-4]; Down 200; 11.8uM; PC3; HT_HG-U133A	APP ITGAL HIVEP3 GRK3 CLU PLCG2 DNAJB5 DAGLA	7.44e-05	199	157	8	4000_DN
Drug	haloperidol; Down 200; 10uM; PC3; HT_HG-U133A	GALK1 TBC1D30 PHF8 APP HEG1 TENM4 GRK2 PC	7.44e-05	199	157	8	1203_DN
Drug	Phenindione [83-12-5]; Up 200; 18uM; MCF7; HT_HG-U133A	DDX51 TSC22D2 APP MMP25 CABIN1 DAGLA PHLPP2 MAF	7.70e-05	200	157	8	5991_UP
Drug	Hypochlorous Acid	GALK1 ING2 RIOK3 VARS2 DENND1A AKR7A2 SBF1 FKTN PRKAR2B PCDHGC3 ZMYM3	8.11e-05	387	157	11	ctd:D006997
Drug	Pl-cs	SUCLG2 PDIA3 GRK2 PLCG2 PLEK CDH5	9.95e-05	107	157	6	CID006450086
Drug	8-N3cAMP	GRK2 GRK3 PRKAR2B	1.11e-04	14	157	3	CID006426627
Drug	8-(6-aminohexyl)amino cyclic AMP	GRK2 GRK3 PRKAR2B	1.11e-04	14	157	3	CID000161999
Drug	AC1L1KS5	GRM1 SUCLG2 PDIA3 RYR1 GRK2 GRK3 PRKAR2B PLCG2 MAPK13 DAGLA	1.13e-04	334	157	10	CID000005631
Drug	GF109203X	APP GRM1 PDIA3 GRK2 GRK3 PRKAR2B PLCG2 PLEK MAPK13 DAGLA	1.33e-04	341	157	10	CID000002396
Drug	NA-382	GRK2 GRK3 PRKAR2B	1.38e-04	15	157	3	CID000132534
Drug	3 SA	GRK2 GRK3 PRKAR2B MAPK13	1.81e-04	41	157	4	CID000449164
Drug	irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A	PDS5B ZEB1 TACC2 MED13L ERBIN TBC1D8 TENM4	1.89e-04	171	157	7	7535_DN
Drug	butaprost	APP GRK2 GRK3 PRKAR2B PPP1R9B	2.06e-04	78	157	5	CID005311035
Drug	Paroxetine	VGF APP GRK2 ARC	2.18e-04	43	157	4	ctd:D017374
Drug	S-2-pentyl-4-pentynoic hydroxamic acid	ZEB1 ABL1 SPTB PI4K2A CYGB ZNF407 RYR1 TBC1D8 HIVEP3 TRAFD1 SUV39H1 ARC PPP1R9B ZNF830 ZMYM3 RAD23B	2.18e-04	834	157	16	ctd:C513635
Drug	AC1L1GTT	ETV4 RYR1 GRK2 GRK3 PTPRN2 NFATC3 PRKAR2B CABIN1	2.20e-04	233	157	8	CID000003837
Drug	8-azido cyclic AMP	GRK2 GRK3 PRKAR2B	2.43e-04	18	157	3	CID000115296
Drug	2,4,4'-trichlorobiphenyl	PRUNE2 ZEB1 DCPS TROAP KIF26B ZNF397 APP BRWD3 ARHGEF15 PRX ACOX3 PITPNM1 FAT2 GRK3 CELSR3 PTPRN2 BEND7 CCDC74A HELZ2 KNDC1 AKAP10 CDH5	2.80e-04	1411	157	22	ctd:C081766
Drug	bisnorbiotin	PC PCCB	2.81e-04	4	157	2	CID000086492
Drug	AC1L955D	PDS5B SPTB	2.81e-04	4	157	2	CID000438204
Drug	Sensodyne	RYR1 TNN	2.81e-04	4	157	2	CID000010589
Drug	Disulfiram [97-77-8]; Up 200; 13.4uM; PC3; HT_HG-U133A	FOXO1 KIAA0232 PI4K2A APP CLU ARC RAD23B	2.86e-04	183	157	7	2053_UP
Drug	8-azidoadenosine	GRK2 GRK3 PRKAR2B	2.87e-04	19	157	3	CID000160751
Drug	8-thiomethyl-cAMP	GRK2 GRK3 PRKAR2B	2.87e-04	19	157	3	CID000093140
Drug	AC1L9W2O	NES STK36 GPT2	2.87e-04	19	157	3	CID000502233
Drug	XeC compound	GRM1 RYR1 PLCG2 CABIN1 CDH5	2.91e-04	84	157	5	CID000005701
Drug	Desipramine	NES GRK2 GRK3 ARC	3.08e-04	47	157	4	ctd:D003891
Drug	Hycanthone [3105-97-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A	VGF TBC1D30 TROAP SMG5 APP NFATC3 CABIN1	3.36e-04	188	157	7	5691_DN
Drug	PDBu	APP ITGAL GRK2 GRK3 CELSR3 PRKAR2B PLEK MAF	3.45e-04	249	157	8	CID000037783
Drug	lipoic acid	AKR7A2 BUD23 MAPK13 PC TXN2 PCCB SORD	3.47e-04	189	157	7	CID000000864
Drug	Pyrimethamine [58-14-0]; Down 200; 16uM; HL60; HG-U133A	RALGDS SMG5 MED13L APP GRK2 SBF1 AKAP10	3.59e-04	190	157	7	1974_DN
Drug	5230742; Up 200; 17uM; MCF7; HT_HG-U133A_EA	FOXO1 SMG5 TRAFD1 CELSR3 SBF1 AKAP10 CABIN1	3.59e-04	190	157	7	970_UP
Drug	2,3-DPG	PDS5B SPTB CYGB GRK2 GRK3 PRKAR2B	3.82e-04	137	157	6	CID000000061
Drug	Leflunomide [75706-12-6]; Down 200; 14.8uM; MCF7; HT_HG-U133A	TBC1D30 PI4K2A SMG5 ZNF236 HEG1 GRK2 MAPK13	3.82e-04	192	157	7	6102_DN
Drug	(2S,3R)-Sphingosine	ITGAL RYR1 GRK2 GRK3 PINX1 PRKAR2B PLCG2 PLEK GPT2 MAPK13	3.82e-04	389	157	10	CID000001104
Drug	Gabapentin [60142-96-3]; Up 200; 23.4uM; MCF7; HT_HG-U133A	PRUNE2 PI4K2A ZNF407 MMP25 EXOC6B PLEK MAF	3.94e-04	193	157	7	7229_UP
Drug	Clotrimazole [23593-75-1]; Down 200; 11.6uM; HL60; HG-U133A	PDS5B RALGDS TBC1D30 MSH3 AKAP10 MPPE1 RAD23B	3.94e-04	193	157	7	1549_DN
Drug	Cyclacillin [3485-14-1]; Up 200; 11.8uM; PC3; HT_HG-U133A	RALGDS SYT17 DDX51 PHF8 SLC9A3 PTPRN2 PRKAR2B	3.94e-04	193	157	7	4536_UP
Drug	Theobromine [83-67-0]; Down 200; 22.2uM; PC3; HT_HG-U133A	GALK1 RPS6KA2 PI4K2A TSC22D2 APP PLCG2 DNAJB5	3.94e-04	193	157	7	6613_DN
Drug	Hexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; HL60; HG-U133A	RIOK3 DPF2 MED13L APP SBF1 HTATSF1 RAD23B	3.94e-04	193	157	7	1982_DN
Drug	Ethopropazine hydrochloride [1094-08-2]; Down 200; 11.4uM; PC3; HT_HG-U133A	RALGDS GALK1 RPS6KA2 PI4K2A APP TENM4 RAD23B	3.94e-04	193	157	7	6697_DN
Drug	Ro 31-8220	GRM1 PDIA3 GRK2 GRK3 PRKAR2B PLCG2 PLEK MAPK13 DAGLA	4.02e-04	321	157	9	CID000005083
Drug	Bromperidol [10457-90-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A	RALGDS ACOX3 TRAFD1 GRK2 KLF5 PLCG2 PC	4.07e-04	194	157	7	7457_DN
Drug	ICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A	VGF TBC1D30 ZNF236 HEG1 TRAFD1 PLEK PCDHGC3	4.07e-04	194	157	7	7534_DN
Drug	Ethambutol dihydrochloride [1070-11-7]; Down 200; 14.4uM; PC3; HT_HG-U133A	RALGDS APP ARC PLCG2 DNAJB5 CABIN1 MPPE1	4.07e-04	194	157	7	4001_DN
Drug	Trihexyphenidyl-D,L Hydrochloride [58947-95-8]; Up 200; 11.8uM; PC3; HT_HG-U133A	VGF ZNF236 HEG1 GRK3 PTPRN2 NFATC3 TNN	4.07e-04	194	157	7	4015_UP
Drug	17-DMAG; Up 200; 0.1uM; PC3; HT_HG-U133A	PRUNE2 PDS5B RALGDS SMG5 CLU TNN CABIN1	4.07e-04	194	157	7	1213_UP
Drug	Butoconazole nitrate [32872-77-1]; Up 200; 8.4uM; PC3; HT_HG-U133A	PDS5B TBC1D30 CDHR2 PI4K2A ARHGEF15 NFATC3 DAGLA	4.19e-04	195	157	7	6288_UP
Drug	Ifenprodil tartrate [23210-58-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	GALK1 TSC22D2 ACOX3 RRP1 MAPK13 ZBTB3 PC	4.19e-04	195	157	7	7404_DN
Drug	Palmatine chloride [3486-67-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A	PI4K2A DDX51 ZNF236 RYR1 HEG1 PLCG2 CABIN1	4.19e-04	195	157	7	2795_UP
Drug	Alfaxalone [23930-19-0]; Down 200; 12uM; HL60; HT_HG-U133A	TBC1D30 PHF8 ACOX3 HEG1 NFATC3 KLF5 CABIN1	4.19e-04	195	157	7	3135_DN
Drug	Picotamide monohydrate [80530-63-8]; Up 200; 10.2uM; PC3; HT_HG-U133A	CDHR2 ZNF407 HIVEP3 CELSR3 ARC DNAJB5 MPPE1	4.19e-04	195	157	7	7140_UP
Drug	Pempidine tartrate [546-48-5]; Up 200; 13uM; HL60; HT_HG-U133A	FOXO1 SPTB GRM1 TRAFD1 CLU KLF5 PCDHGC3	4.19e-04	195	157	7	2172_UP
Drug	Deoxycorticosterone [64-85-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A	RIOK3 SMG5 DPF2 APP TRAFD1 PLCG2 CABIN1	4.19e-04	195	157	7	5357_DN
Drug	Cimetidine [51481-61-9]; Up 200; 15.8uM; PC3; HT_HG-U133A	PRUNE2 SPTB PHF8 ACOX3 GRK2 PTPRN2 PLCG2	4.19e-04	195	157	7	4063_UP
Drug	isatin	ZEB1 PRPF6 AKR7A2 PTPRN2	4.23e-04	51	157	4	CID000007054
Drug	BAPTA	GRM1 RYR1 GRK2 GRK3 NFATC3 PRKAR2B PLEK MAPK13 CABIN1	4.30e-04	324	157	9	CID000104751
Drug	Pepstatin A [26305-03-3]; Down 200; 5.8uM; PC3; HT_HG-U133A	PI4K2A GRM1 HEG1 SLC9A3 GRK3 DNAJB5 MAF	4.32e-04	196	157	7	4206_DN
Disease	Parkinson's disease (biomarker_via_orthology)	ABL1 GRK2 GRK3 PPP1R9B	1.43e-05	30	146	4	DOID:14330 (biomarker_via_orthology)
Disease	venous thromboembolism, fibrinogen measurement	CYP21A2 TRAFD1 PLCG2 PLEK PCCB	2.09e-05	67	146	5	EFO_0004286, EFO_0004623
Disease	glycine measurement, amino acid measurement	CYP21A2 PKD1L2	1.45e-04	4	146	2	EFO_0005134, EFO_0009767
Disease	urinary metabolite measurement	RPS6KA2 CYP21A2 SUCLG2 AKR7A2 MMP25 CABIN1 SORD	2.28e-04	245	146	7	EFO_0005116
Disease	bilirubin measurement	ABL1 ING2 HLA-DQB1 CYP21A2 SPTB ZNF407 SMG5 PKD1L2 PCCB	3.71e-04	442	146	9	EFO_0004570
Disease	platelet component distribution width	PRUNE2 PDS5B GAPVD1 SRSF3 KIAA0232 CYP21A2 ARHGEF15 TNN PPP1R9B PLCG2 PLEK MAF	3.91e-04	755	146	12	EFO_0007984
Disease	serum alanine aminotransferase measurement	PDS5B GALK1 HLA-DQB1 CYP21A2 TSC22D2 MMP25 TBC1D8 TRAFD1 TENM4 GSDMD PINX1 PCCB SORD	3.98e-04	869	146	13	EFO_0004735
Disease	Manic Disorder	RPS6KA2 TENM4 GRK3 PC	4.32e-04	71	146	4	C0024713
Disease	risk-taking behaviour	GAPVD1 ZNF618 HLA-DQB1 RASSF10 MSH3 DENND1A HIVEP3 TENM4 PTPRN2 TTC29 PINX1 PC	4.35e-04	764	146	12	EFO_0008579
Disease	Manic	RPS6KA2 TENM4 GRK3 PC	6.18e-04	78	146	4	C0338831
Disease	Bipolar Disorder	VGF SRSF3 RPS6KA2 APP TENM4 GRK3 AKAP10 PC MPPE1	6.41e-04	477	146	9	C0005586
Disease	Depression, Bipolar	RPS6KA2 TENM4 GRK3 PC	6.48e-04	79	146	4	C0005587
Disease	late-onset Alzheimers disease	APP TENM4 CLU PLCG2 TXN2 MAF RAD23B	6.51e-04	292	146	7	EFO_1001870
Disease	pulmonary hypertension (biomarker_via_orthology)	PDIA3 RYR1 CLU CDH5	6.80e-04	80	146	4	DOID:6432 (biomarker_via_orthology)
Disease	Inflammatory Bowel Diseases	IL10RA ITGAL PLCG2	6.92e-04	35	146	3	C0021390
Disease	zinc fingers and homeoboxes protein 3 measurement	HLA-DQB1 CYP21A2	8.56e-04	9	146	2	EFO_0803299
Disease	Mental deterioration	APP CLU	8.56e-04	9	146	2	C0234985
Disease	Mild cognitive disorder	APP CLU	8.56e-04	9	146	2	C1270972
Disease	worry measurement	GAPVD1 HLA-DQB1 RASSF10 PCCB BAG6	1.04e-03	154	146	5	EFO_0009589
Disease	3-methylglutarylcarnitine (2) measurement	CYP21A2 SUCLG2	1.30e-03	11	146	2	EFO_0800074
Disease	fibrinogen measurement, tissue plasminogen activator measurement	CYP21A2 TRAFD1 PCCB	1.45e-03	45	146	3	EFO_0004623, EFO_0004791
Disease	fibrinogen measurement, plasminogen activator inhibitor 1 measurement	CYP21A2 TRAFD1 PCCB	1.45e-03	45	146	3	EFO_0004623, EFO_0004792
Disease	Acute Confusional Senile Dementia	APP CLU ARC PLCG2	1.50e-03	99	146	4	C0546126
Disease	Alzheimer's Disease, Focal Onset	APP CLU ARC PLCG2	1.50e-03	99	146	4	C0750900
Disease	Alzheimer Disease, Early Onset	APP CLU ARC PLCG2	1.50e-03	99	146	4	C0750901
Disease	Presenile dementia	APP CLU ARC PLCG2	1.50e-03	99	146	4	C0011265
Disease	Alzheimer Disease, Late Onset	APP CLU ARC PLCG2	1.50e-03	99	146	4	C0494463
Disease	Congenital muscular dystrophy	RYR1 FKTN	1.55e-03	12	146	2	cv:C0699743
Disease	Familial Alzheimer Disease (FAD)	APP CLU ARC PLCG2	1.56e-03	100	146	4	C0276496
Disease	Alzheimer's Disease	APP CLU ARC PLCG2	1.62e-03	101	146	4	C0002395
Disease	pneumonia	HLA-DQB1 TRAPPC12 HELZ2	1.64e-03	47	146	3	EFO_0003106
Disease	autoimmune hepatitis (is_implicated_in)	HLA-DQB1 PDIA3	1.83e-03	13	146	2	DOID:2048 (is_implicated_in)
Disease	Charcot-Marie-Tooth disease type 4	PRX SBF1	1.83e-03	13	146	2	cv:C4082197
Disease	Fanconi anemia	FANCF SLX4	2.13e-03	14	146	2	cv:C0015625
Disease	triacylglycerol 48:4 measurement	ZNF236 TENM4	2.13e-03	14	146	2	EFO_0010407
Disease	Impaired cognition	APP CLU	2.13e-03	14	146	2	C0338656
Disease	diet measurement	KIF26B ZNF618 HLA-DQB1 SYT17 RIOK3 MSH3 TENM4 EXOC6B AKAP10 PLCG2 PCDH10 PCCB DAGLA	2.19e-03	1049	146	13	EFO_0008111
Disease	X-12063 measurement	ZSCAN25 CLU EXOC6B PCDH10 MAF	2.38e-03	186	146	5	EFO_0021283
Disease	myeloid white cell count	PRUNE2 ABL1 CYP21A2 RIOK3 ITGAL PRX TBC1D8 HIVEP3 BEND7 TTC29 PINX1 PLEK	2.47e-03	937	146	12	EFO_0007988
Disease	lymphocyte count	ABL1 SELENBP1 HLA-DQB1 KIAA0232 CYP21A2 SPTB VARS2 ZSCAN25 MED13L ARHGEF15 TENM4 PINX1 PLEK CORO7 ARRDC2 PCDHGC3	2.48e-03	1464	146	16	EFO_0004587
Disease	factor VII activating protease measurement	SRSF3 HELZ2 EXOC6B	2.58e-03	55	146	3	EFO_0009368
Disease	factor XI measurement, fibrinogen measurement, tissue plasminogen activator measurement, factor VII measurement	CYP21A2 TRAFD1 PCCB	2.72e-03	56	146	3	EFO_0004619, EFO_0004623, EFO_0004694, EFO_0004791
Disease	chronic lymphocytic leukemia	KRT32 HLA-DQB1 APP CSRNP1	2.94e-03	119	146	4	EFO_0000095
Disease	renal fibrosis (implicated_via_orthology)	CYGB CLU	3.15e-03	17	146	2	DOID:0050855 (implicated_via_orthology)
Disease	acne	NAALADL1 RASSF10 PIM3 PINX1	3.51e-03	125	146	4	EFO_0003894
Disease	Bone marrow hypocellularity	FANCF SLX4	3.53e-03	18	146	2	C1855710
Disease	bipolar disorder (is_marker_for)	SRSF3 GRK3	3.93e-03	19	146	2	DOID:3312 (is_marker_for)
Disease	citrulline measurement	KIF26B CYP21A2	4.36e-03	20	146	2	EFO_0009777
Disease	memory performance	PDS5B TBC1D30 RASSF10 ERBIN ZFYVE28 HIVEP3 PXDN	4.37e-03	409	146	7	EFO_0004874
Disease	phospholipids:total lipids ratio, intermediate density lipoprotein measurement	HLA-DQB1 CYP21A2 PCCB	4.51e-03	67	146	3	EFO_0008595, EFO_0020946
Disease	Schizophrenia	IL10RA SELENBP1 HLA-DQB1 GRM1 PITPNM1 TENM4 CLU KLF5 ARC PPP1R9B BECN1	4.57e-03	883	146	11	C0036341
Disease	chronic myeloid leukemia (is_implicated_in)	ABL1 HLA-DQB1	4.80e-03	21	146	2	DOID:8552 (is_implicated_in)
Disease	venous thromboembolism, plasminogen activator inhibitor 1 measurement	PLCG2 PLEK	4.80e-03	21	146	2	EFO_0004286, EFO_0004792

Protein segments in the cluster

Peptide	Gene	Start	Entry
DIVVNPPVAGEESFE	GPT2	386	Q8TD30
PPVAGEESFEQFSRE	GPT2	391	Q8TD30
PFRPDDDGIFVTRVQ	ERBIN	1346	Q96RT1
DDGIFVTRVQPEGPA	ERBIN	1351	Q96RT1
FIPEGLSENQDEVEP	BUD23	211	O43709
IPPRGEVNAADAFDI	GRK3	471	P35626
EEGPLEPAVVDAFNQ	AKR7A2	331	O43488
GDATPDNIPADIVFV	DNAJB5	231	O75953
NVAVPEAAEERAEPG	EIF3B	6	P55884
ATRRQFGPTEEEEIP	ACOX3	331	O15254
EVQGAERASPEPQRE	BAG6	956	P46379
ANTENEVEPVDARPA	APP	631	P05067
VSDLGQFIRESEPEP	AKAP10	591	O43572
SPGVDTQIFEDPREF	ARC	206	Q7LC44
EPDAAEPDVQRGRSF	GSDMD	66	P57764
FPDEVGAGVPVSQEE	BRWD3	1111	Q6RI45
QDADAPEPGLQARAD	ARHGEF15	166	O94989
AERPESQEAEPVAGF	C1orf232	151	A0A0U1RR37
RVAIEPGAPRENDEF	SORD	91	Q00796
EGSQRPQAAPEEASF	CCDC74A	301	Q96AQ1
PQAAPEEASFPRDQE	CCDC74A	306	Q96AQ1
EGSQRPQAVPEEASF	CCDC74B	301	Q96LY2
PQAVPEEASFPRDQE	CCDC74B	306	Q96LY2
ADRIVFENPDPSDGF	DCPS	186	Q96C86
SVGSLFVEDPDEPQN	CDH5	276	P33151
ERQTGAAADIPQPAF	FAM90A10	201	A6NDY2
VADTEEAALGQSPFP	ARRDC2	346	Q8TBH0
IPPRGEVNAADAFDI	GRK2	471	P25098
AEAQVPDSDEQFVPD	ETV4	66	P43268
AEEAAAAPPLAGEAQ	RASSF10	301	A6NK89
GDRESQAVVDPPQAA	RAD23B	231	P54727
DVFQGSSPVDDIPQE	PDS5B	1411	Q9NTI5
AEGPATVQSVEDFVP	RABL6	381	Q3YEC7
FQDDVDLEDQPRGSP	RABL6	441	Q3YEC7
GESLDSVPAQIPEDF	RIMBP3B	1171	A6NNM3
GESLDSVPAQIPEDF	RIMBP3C	1171	A6NJZ7
ERQTGAAADIPQPAF	FAM90A7	201	A6NKC0
VQDEEVGLPFEASPE	NIBAN2	626	Q96TA1
AQDRPPAEGDDRFSE	PTPRN2	176	Q92932
IPLDSAFDPDVGENS	PCDH18	156	Q9HCL0
DVEFPIRADVQGPAA	ZFYVE28	291	Q9HCC9
EPGAQDSPEAFRSED	RADIL	751	Q96JH8
NPEVGEAREVFDLPV	PAXIP1	56	Q6ZW49
QEAPDVVAFVAPGES	PAGE4	16	O60829
DSPQGQEPDILIDFA	MMP25	161	Q9NPA2
LDPGAAEQVPDFVTF	MSH3	1041	P20585
FPGPGVRDADEETLQ	FANCF	116	Q9NPI8
SDDAEFRPPELQGER	MED13L	641	Q71F56
LNPEALGFSPEDAVE	MAF	101	O75444
AESFRELEAPAQGSP	CSRNP1	306	Q96S65
GFPETPVDDEQQAAT	KIF26B	1146	Q2KJY2
GDRLNIEVDAAPPVD	KRT32	246	Q14532
ANEDSVPGADDFVPV	GAPVD1	1411	Q14C86
PNSFEGAEEEAVQTP	LBHD1	201	Q9BQE6
ETNSGEEPFIETPRQ	BECN1	61	Q14457
EEPFIETPRQDGVSR	BECN1	66	Q14457
GDPVFDPDQRGDVVL	DUOX2	136	Q9NRD8
NREDPLPQDSFEGVD	CORO7	906	P57737
RAQPGTPVAIEEEFS	CYP21A2	151	P08686
SGEDAAPAEERDIPF	MPPE1	261	Q53F39
PVAVVFARDPDQGAN	FAT2	3131	Q9NYQ8
EDNPVSSGQLEEFPV	KIAA0232	1256	Q92628
DAGDHVQPPEGRDFT	PINX1	276	Q96BK5
TRVVDGAFFPNEPLD	CES5A	311	Q6NT32
REEFGAEPELAVSAP	GALK1	21	P51570
EAEAPRGAEEAFPAE	NES	1176	P48681
FRDPEEETEAQQPFD	MAPK13	311	O15264
EEGEPATQRQDPAAA	GAGE2D;	41	Q9UEU5
EEGEPATQRQDPAAA	GAGE2A	41	Q6NT46
EVPGEEDPAAVAFQG	IL10RA	431	Q13651
EEVPGAQDLVDFSPV	EXOC6B	281	Q9Y2D4
RVTGNPGDEEFIEPS	HEG1	386	Q9ULI3
QGDPPVEFATDRVEE	PLCG2	881	P16885
VTEDSPEARAEFPSG	PCDHGC3	666	Q9UN70
VFETPEAQPGAERSF	PCDH10	986	Q9P2E7
QEREASPVEFAIDPN	ING2	196	Q9H160
GQFIRSVDPDSPAEA	SLC9A3R1	176	O14745
LADPDTPVFERGAVD	PKD1L2	1426	Q7Z442
LAPAQEVGEAPSQED	SBF1	706	O95248
EEEDAEAPPSFSGAQ	NUTM1	476	Q86Y26
PDGVASVSFRDPEEA	HTATSF1	311	O43719
RNEFPEDPEFEAVVR	PI4K2A	101	Q9BTU6
ANPFPAAVRGFVDDI	PCCB	491	P05166
QPQEAAREADAVAPG	GASK1B	151	Q6UWH4
STPVAEGRDSPEDFV	HLA-DQB1	26	P01920
PDAEAFSVSPERAVG	CDHR2	411	Q9BYE9
EDFPQAPGSVAAAVA	FOXO1	81	Q12778
EELARVAEGTSFPPQ	CABIN1	2016	Q9Y6J0
PRVVAAAFQSEDPAD	DDX51	386	Q8N8A6
ANITAEDPDDEGFPS	CDHR3	256	Q6ZTQ4
EEGEPATQRQDPAAA	GAGE10	41	A6NGK3
AEEFASDFPPETQRA	CYGB	136	Q8WWM9
VADQTRDGPEPEAER	CCDC102A	166	Q96A19
QPRPEEAAEFQAEFV	GRHPR	186	Q9UBQ7
RPVASDFEPQGLSEA	ABL1	31	P00519
PGAFDRPELQQVTVD	FKTN	211	O75072
EINISFVPESPDGQE	RALGDS	721	Q12967
ARPRFAPGVTIEEDN	DAGLA	331	Q9Y4D2
GTLSDPEVQRQFPED	DENND1A	26	Q8TEH3
EEAAPADAGAFNAPV	PRKAR2B	91	P31323
AEAPADPRDASGEAQ	KNDC1	406	Q76NI1
PSSDPEVQLAEGFDV	BEND7	276	Q8N7W2
NDNAPVFPAEEFEVR	CELSR3	1061	Q9NYQ7
SEQAEASEFPVPRVG	HELZ2	2246	Q9BYK8
NVEEEEDAQPIRFSP	GRM1	956	Q13255
AEGNFDPRPVETLNV	RYR1	2731	P21817
EPEDGVEGRAFQVDP	CDH16	381	O75309
GDSEQFIDEERQGPP	PRH1;	36	P02810
AFPVDGEPDAEVVVG	VARS2	321	Q5ST30
EAAEIEPEAQAQRSP	STK11IP	586	Q8N1F8
APEVRGARNSEPQDE	VGF	56	O15240
PRSLDFGDVPIDSDV	PRUNE2	1486	Q8WUY3
SSPRGVEEPDVIFQN	TRAFD1	326	O14545
AELEEGENPVPAFQS	SMG5	401	Q9UPR3
QSSEDEVEILGPFPA	SYT17	41	Q9BSW7
FSIAIPVDGDEDRNP	TSC22D2	641	O75157
GESLDSVPAQIPEDF	RIMBP3	1171	Q9UFD9
RSDIGPARDANDPVD	PRPF6	31	O94906
QAGPASVPLRTEEEF	PDIA3	131	P30101
VDGTAENPFLDNPDA	PLEK	201	P08567
GIDNPVFSPDEALDR	SLC9A3	751	P48764
EEGEPATQRQDPAAA	GAGE2B	41	Q13066
APNVLRDGFNPADVE	SELENBP1	206	Q13228
VGADPEARAEAGEQP	RRP1	396	P56182
DDTFIGNEPLTPEVR	ITGAL	386	P20701
TVENEVDLDGPPRAF	SUV39H1	146	O43463
FPEERPEVLGQRSTD	STK36	391	Q9NRP7
SGARGAEAPEQEAPE	SLX4	936	Q8IY92
PATVTAFVFEEDGAP	ADD2	401	P35612
AFQHPPTEFIREGDD	CLU	266	P10909
DGPDFQDRVVNSETP	TXN2	66	Q99757
EEAAVFPEVAVAEGP	RIOK3	51	O14730
FIDAFASPVEAEGTP	PITPNM1	376	O00562
DATQVEVNPFGETPE	SUCLG2	236	Q96I99
SVEGAPENRADPFDQ	ZNF618	216	Q5T7W0
PENRADPFDQGVVAT	ZNF618	221	Q5T7W0
FDDPVRIQEEATNPD	PHLPP2	116	Q6ZVD8
VARNPPGFAFVEFED	SRSF3	41	P84103
VQVDADPQPLSDDGA	TNN	56	Q9UQP3
AREVPGSEAARPEQE	TRAPPC12	136	Q8WVT3
FPTAEQEPGEVVDSL	SPIN4	186	Q56A73
GVPADLAPVDVEFSF	PRX	146	Q9BXM0
TPQDSQAFPEAAERD	TBC1D8	1066	O95759
PGDETRAFQEQALPV	ZSCAN25	186	Q6NSZ9
VNVPDVSRNGDPFVA	PXDN	611	Q92626
EEDAPASQRGEPARI	HIVEP3	1716	Q5T1R4
QTEAPGTIEFVADPA	TROAP	111	Q12815
PEDREPNFATIGLQD	NFATC3	1016	Q12968
PRVDDDSLGEFPVTN	DPF2	136	Q92785
PPEGNASVIQDFTED	TENM4	1981	Q6N022
APGDIAAAFPAERDS	TACC2	146	O95359
IEGQSPEPVFGDADV	TBC1D30	796	Q9Y2I9
PEPVFGDADVDVSAV	TBC1D30	801	Q9Y2I9
GEVEAQDSDPAPAFS	RFC2	11	P35250
AQGFPEEFRDSPDVT	SPTB	806	P11277
PEPAQDLFDFITERG	PIM3	126	Q86V86
AVIFPEAPEEDQRQG	ZEB1	136	P37275
NIEPDPVTEEFRGST	TTC29	436	Q8NA56
EDLEREFDDPGQQVP	ZNF397	126	Q8NF99
LPEGFFDDPEVDARV	ZNF830	246	Q96NB3
DQPLEADEDGFVAPQ	ZNF236	841	Q9UL36
DPNRVREPGEVEFDI	PHF8	686	Q9UPP1
QISSEPEDFAQPGDV	ZNF407	991	Q9C0G0
VRVAAPPNDGQEETA	ZSCAN29	496	Q8IWY8
FGDILQRPNDPETVE	RPTN	41	Q6XPR3
EDPARSFQPDTGRIE	PC	381	P11498
VDDPNDEDFVPFRPR	ZMYM3	271	Q14202
QERPSQAAPAVEAEG	TXLNA	31	P40222
TDVSDEQPQGPERAF	ZBTB3	366	Q9H5J0
AANPARDAALFPGEE	KLF5	36	Q13887
FANGPDDTPEEILAR	RPS6KA2	611	Q15349
FRPDGDFPADSQVNV	NAALADL1	321	Q9UQQ1
VGNGRAPDVAPEEVD	PPP1R9B	366	Q96SB3